GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sonoma Pharmaceuticals Inc (STU:O8Z) » Definitions » Net Cash per Share

Sonoma Pharmaceuticals (STU:O8Z) Net Cash per Share : €-5.97 (As of Jun. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sonoma Pharmaceuticals Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Sonoma Pharmaceuticals's Net Cash per Share for the quarter that ended in Jun. 2024 was €-5.97.

The historical rank and industry rank for Sonoma Pharmaceuticals's Net Cash per Share or its related term are showing as below:

During the past 13 years, the highest Price-to-Net-Cash Ratio of Sonoma Pharmaceuticals was 697.50. The lowest was 1.50. And the median was 4.23.

STU:O8Z's Price-to-Net-Cash is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.49
* Ranked among companies with meaningful Price-to-Net-Cash only.

Sonoma Pharmaceuticals Net Cash per Share Historical Data

The historical data trend for Sonoma Pharmaceuticals's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonoma Pharmaceuticals Net Cash per Share Chart

Sonoma Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -53.43 -43.38 -16.11 -16.79 -6.45

Sonoma Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.34 -21.07 -7.40 -6.45 -5.97

Competitive Comparison of Sonoma Pharmaceuticals's Net Cash per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sonoma Pharmaceuticals's Price-to-Net-Cash Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Sonoma Pharmaceuticals's Price-to-Net-Cash falls into.



Sonoma Pharmaceuticals Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Sonoma Pharmaceuticals's Net Cash per Share for the fiscal year that ended in Mar. 2024 is calculated as

Net Cash per Share (A: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(2.878-7.915-0)/0.78037
=-6.45

Sonoma Pharmaceuticals's Net Cash per Share for the quarter that ended in Jun. 2024 is calculated as

Net Cash per Share (Q: Jun. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(2.405-8.08-0)/0.95022
=-5.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sonoma Pharmaceuticals  (STU:O8Z) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Sonoma Pharmaceuticals Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Sonoma Pharmaceuticals Business Description

Traded in Other Exchanges
Address
5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, and other countries.

Sonoma Pharmaceuticals Headlines

No Headlines